$8.63
Value $258M
QTTB and TMO stock compared: price, dividend, valuation and results, from SEC filings.
$8.63
Value $258M
$686.79
Value $255B
Q32 Bio (QTTB) has a market value of $258M and Thermo Fisher Scientific (TMO) $255B. Over the last year, with dividends, QTTB moved +299.5% and TMO +19.1%. The P/E is 8.0 for QTTB and 36.1 for TMO. Dividend yield: QTTB none, TMO 0.27%.
The main figures of both. A bar only shows which number is larger, not which is better.
Market value
QTTB$258M
TMO$255B
TMO is 988 times QTTB
Revenue, 12 months
QTTB$54M
TMO$47.4B
TMO is 881 times QTTB
Net income, 12 months
QTTB$32M
TMO$7.1B
TMO is 219 times QTTB
Operating margin
QTTB31.5%
TMO17.9%
13.6 points apart
ROIC
QTTB31.8%
TMO8.2%
23.6 points apart
P/E
QTTB8.0
TMO36.1
TMO is 4.5 times QTTB
Dividend yield
QTTB0.0%
TMO0.3%
0.3 points apart
5-year return
QTTB-91.6%
TMO+8.6%
100.2 points apart
A fainter bar means a negative number. The 5-year return includes dividends.
Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.
QTTB-91.6%
TMO+8.6%
| Period | QTTBWith dividends | TMOWith dividends |
|---|---|---|
| 1 year since November 14, 2025 | +299.5%Price +299.5% | +19.1%Price +18.7% |
| 3 years since November 17, 2023 | -14.4%-5.0% a yearPrice -14.4% | +48.7%+14.1% a yearPrice +47.2% |
| 5 years since November 16, 2021 | -91.6%-39.1% a yearPrice -91.6% | +8.6%+1.7% a yearPrice +7.1% |
Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.
As on each company's page. A description, not a recommendation: no one figure says which is better.
QTTBQ32 BioTMOThermo Fisher Scientific
| Price | $8.63 | $686.79 |
|---|---|---|
| Market value | $258M | $255B |
| Enterprise value (EV) | – | $290B |
| P/E | 8.0 | 36.1 |
| P/E, 5-year median | – | 32.7 |
| P/B | 0.9 | 4.7 |
| EV/EBIT | – | 34.3 |
| Free cash flow yield | – | 3.0% |
| Revenue, 12 months | $54M | $47.4B |
|---|---|---|
| Net income, 12 months | $32M | $7.1B |
| Free cash flow, 12 months | -$20M | $7.6B |
| Earnings per share, 12 months | $1.08 | $18.96 |
| Revenue growth, year on year | – | 3.9% |
| Revenue growth a year, past | +81.9%over 5 years | +6.7%over 5 years |
| EPS growth a year, past | – | +2.1%over 5 years |
| Gross margin | – | – |
|---|---|---|
| Operating margin | 31.5% | 17.9% |
| Net margin | 55.5% | 14.9% |
| ROIC | 31.8% | 8.2% |
| ROE | 34.8% | 13.4% |
| Cash | $290M | $6.1B |
|---|---|---|
| Total debt | $8.6M | $41.4B |
| Net debt / EBITDA | -16.6 | 3.7 |
| Interest cover | – | 5.5× |
| Dividend yield | – | 0.3% |
|---|---|---|
| Dividend per share, 12 months | – | $1.84 |
| Dividend growth a year, past | – | +14.3%over 5 years |
| Buyback yield | – | 1.2% |
| Shareholder yield | – | 1.5% |
Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.
By market value, Thermo Fisher Scientific ($255B) is about 988.0 times Q32 Bio ($258M), at today's prices.
Since November 16, 2021, QTTB's price moved -91.6% and TMO's +7.1%. With dividends: QTTB -91.6% (-39.1% a year), TMO +8.6% (+1.7% a year). Past returns do not predict future ones.
The dividend yield at today's price is none for Q32 Bio and 0.27% for Thermo Fisher Scientific. Over the last twelve months they paid – and $1.84 per share.
At today's price, the P/E is 8.0 for QTTB and 36.1 for TMO. It is the share price over the last twelve months' earnings per share.
Over the last twelve months, the net margin was 55.5% for Q32 Bio and 14.9% for Thermo Fisher Scientific, and the operating margin 31.5% and 17.9%. Revenue was $54M and $47.4B.
The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.
With each of the two, and with the largest in its sector.
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
Descriptive data from SEC filings and market prices.